Table 11.
Interaction between lncRNAs and PDCD in different conditions.
| Disease | LncRNA | Animal-human | Cell lines | Targets | Function | Ref |
|---|---|---|---|---|---|---|
| Myocardial Infarction (MI) | MALAT1 | Female C57BL/6 mice | AC16 | PDCD4, miR-200a-3p, IL-1, IL-8, TNF-α, Bcl-2, Bax, Cyclin-D1 |
Downregulation of MALAT1 by targeting the miR-200a-3p/PDCD4 axis could improve cell viability and suppress cell apoptosis in the hypoxia-induced myocardial cells. | (98) |
| Stroke | MEG3 | Male C57BL/6 J mice | N2a | PDCD4, miR-21 |
Downregulation of MEG3 could protect against ischemic damages and enhance overall neurological functions in vivo. | (90) |
| Polycystic Ovarian Syndrome (PCOS) | CiRS-126 | Female CF1 mice/Human: 18 PCOS patients and 5 healthy controls | – | PDCD4, miR-21, ROS, Bcl-2, Bax |
Downregulation of ciRS-126 by targeting the miR-21/PDCD4 axis could decrease proliferation and enhance apoptosis in PCOS granulosa cells. | (100) |
| Endometrial Carcinoma (EC) | Lnc-OC1 | 28 pairs of EC and adjacent normal tissues | Ishikawa, HESCs | PD-L1, miR-34a |
Downregulation of Lnc-OC1 by targeting PD-L1 could suppress cell growth and enhance cell apoptosis of EC cells. | (69) |
| Non-Small Cell Lung Carcinoma (NSCLC) |
MALAT1 | 113 pairs of NSCLC and adjacent normal tissues | A549, CAL-12T |
PD-L1, miR-200a-3p |
Upregulation of MALAT1 by targeting the miR-200a-3p-PD-L1 axis could increase proliferation, mobility, migration, and invasion of NSCLC cells. | (99) |
| Diffuse Large B Cell Lymphoma (DLBCL) | SNHG14 | BALB/c mice/Human: 38 pairs of DLBCL and adjacent normal tissues |
GM12878, 293T, A20), OCI-LY7, DB, U2932, FARAGE | PD-1, ZEB1, miR-5590-3p, E-cadherin, N-cadherin |
Upregulation of SNHG14 by targeting PD-1-miR-5590 axis could enhance proliferation, invasion, and EMT in DLBCL. | (101) |
| Lung Adenocarcinoma (LUAD) | circRNA-002178 | 105 pairs of LUAD and adjacent normal tissues | A549, PC9, 95D, BEAS-2B |
PDL1/PD1 | Upregulation of circRNA-002178 could enhance PDL1/PD1 expression in LUAD. | (69) |
| Pancreatic Cancer (PC) | LINC00473 | 134 PC patients and 20 healthy controls | SW‐1990, Panc‐1, BxPC‐3, AsPC‐1, CAPAN‐2, H6C7 |
PD‐L1, miR‐195‐5p, Bcl‐2, Bax, IFN‐γ, IL‐4, MMP‐2/9/10 |
Downregulation of LINC00473 by targeting PD‐L1 could increase apoptosis and decrease proliferation, invasion, and migration of the PC cells. | (102) |